AMGN logo

AMGEN INC

AMGNNASDAQ
πŸ† #50 by market capEarnings Feb 2 Β· Post🧬Biotech
$435.64β–Ό $0.65 (βˆ’0.15%)
Market closed Β· at close
πŸ””
Track AMGN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.1%
7dβ–Ό 6.4%
14dβ–Ό 5.3%
30dβ–Ό 0.8%
ytdβ–² 33.1%
1yβ–² 29.1%
🏦Market Cap
$235.52B
Large Cap
πŸ“ˆRevenue Growth (YoY)
8.2%
Slowing
πŸ“ŠGross Margin
74.7%
High
πŸ’΅FCF Margin
26.1%
Strong
βš–οΈP/S Ratio
6.1x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$434.60 – $445.49
52-Week Range
$312.39 – $483.99
Volume (shares)
4,942,537
Avg Volume (shares)
β€”
Shares Outstanding
540.6M
Next Earnings
2027-02-02

Fundamentals Snapshot

Annual Revenue
$36.74B
Last Q Revenue
$10.37B
P/E Ratio
25.1
P/S Ratio
6.1x
EPS (TTM)
$17.25
Dividend Yield
2.24%
Dilution (1yr)
+0.2%
AMGN logo

AMGEN INC

AMGN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$36.7Bβ–² +9.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.8%β–² +15.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$10.7Bβ–² +47.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$8.1Bβ–Ό βˆ’22.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
543.0Mβ–² +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$45.5Bβ–² +$2.7B YoY
StockOtter Β· stockotter.space

About AMGEN INC

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehΓ§et's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100
Analyst data unavailable.

Latest News & Updates

24/7 Wall StreetΒ·12h ago

Invest $225,000 in These 4 Dividend Stocks and Collect Quarterly Income in Retirement

Retirement changes the question a portfolio has to answer. While you're working, the focus is on how big the balance can grow.

Zacks Investment ResearchΒ·2d ago

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Business WireΒ·4d ago

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Amgen Securities Litigation

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Amgen Securities Litigation: UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE AMGEN IN

Defense WorldΒ·4d ago

Amgen Inc. $AMGN Shares Acquired by Banco Santander S.A.

Banco Santander S.A. grew its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 15.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institu

24/7 Wall StreetΒ·5d ago

Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500

Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?

Seeking AlphaΒ·5d ago

The Winners Inside SCHD - November 2026

The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twi